Ginette-35
Ginette-35 Price range: $ 79,00 through $ 269,00
Back to products
Glucophage Trio
Glucophage Trio Price range: $ 96,00 through $ 187,00

Glucophage

Price range: $ 28,00 through $ 97,00

Glucophage is a widely used medication primarily prescribed for the effective management of type 2 diabetes. It works by helping the body restore its natural response to insulin and decreasing the amount of sugar produced by the liver. By maintaining stable blood glucose levels, this treatment helps prevent serious long-term complications such as kidney damage, nerve problems, and vision loss. Consistent use of Glucophage can also lower the risk of cardiovascular events, including heart attacks and strokes. This oral medication is most effective when combined with a balanced diet and a regular exercise program to improve overall metabolic health.

Active substance: metformin
SKU: Glucophage Category:
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM

Each dosage option has its own packaging choices.

Description

Glucophage – Information for Patients and Caregivers

Glucophage belongs to a group of medicines called biguanides. It is an oral prescription medication prescribed to help manage blood glucose levels in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus.

This reference overview details the clinical characteristics, pharmacokinetic mechanisms, dosage guidelines, and essential safety considerations for Glucophage based on official FDA prescribing documentation.

Attribute Details
Active ingredient (INN) Metformin hydrochloride
Therapeutic class Biguanide (AHFS 68:20.04)
Dosage form Oral tablet
Route of administration Oral
Primary purpose Glycemic control in Type 2 Diabetes Mellitus
Prescription status Prescription only (Rx)

How the drug works

Glucophage decreases blood glucose concentrations without stimulating endogenous insulin secretion, thereby avoiding direct treatment-induced hypoglycemia. Its therapeutic action relies on three primary physiological mechanisms. First, it decreases hepatic gluconeogenesis, reducing basal and postprandial liver glucose production. Second, it increases peripheral insulin sensitivity in skeletal muscle tissue, enhancing tissue glucose uptake and utilization. Third, it delays intestinal glucose absorption. Because basal insulin secretion remains unchanged while tissue responsiveness improves, hyperinsulinemia is reduced, supporting stabilized glycemic control.

What it’s used for

The primary FDA-approved indication for Glucophage is the management of type 2 diabetes mellitus in adult and pediatric patients (10 years of age and older) as monotherapy or combined with other antihyperglycemic agents or insulin. Glucophage is not indicated for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis. In clinical practice, healthcare providers may sometimes evaluate metformin formulations for off-label indications, such as polycystic ovary syndrome (PCOS) or metabolic risk management in prediabetes; however, these applications represent off-label uses not formally approved by the FDA for this brand name.

Dosing schedule

Dosage regimens must be individualized based on clinical effectiveness and patient tolerance while staying within maximum recommended thresholds. The standard starting dose of immediate-release Glucophage is 500 mg orally twice daily or 850 mg once daily, administered with meals to minimize gastrointestinal discomfort. Dosage increases are generally implemented in increments of 500 mg weekly or 850 mg every two weeks, up to a maximum daily dose of 2550 mg in adult patients. Pediatric patients aged 10 to 16 years typically initiate treatment at 500 mg twice daily, with a maximum recommended daily dose of 2000 mg given in divided doses. Renal function must be evaluated via estimated glomerular filtration rate (eGFR) prior to initiating therapy.

What happens in the body

Following oral administration, the absolute bioavailability of Glucophage 500 mg under fasting conditions is approximately 50% to 60%. Administration with food decreases the extent of absorption and slightly delays peak plasma concentrations. Metformin is negligibly bound to plasma proteins, partitioning predominantly into erythrocytes and peripheral tissues. The apparent volume of distribution averages approximately 654 ± 358 liters. Metformin does not undergo hepatic metabolism and is excreted completely unchanged in the urine via glomerular filtration and active tubular secretion. In patients with normal renal function, the plasma elimination half-life is approximately 6.2 hours.

Compatibility with other medicines

Cationic drugs that are eliminated by renal tubular secretion (such as cimetidine, ranitidine, quinidine, and dolutegravir) have the potential to compete for common renal transport systems, potentially increasing systemic exposure to metformin. Concomitant administration with iodinated contrast media used for radiological procedures poses an elevated risk of contrast-induced nephropathy, which can lead to acute renal failure and metformin accumulation; therapy must be temporarily discontinued prior to or at the time of such procedures. Drugs that induce hyperglycemia, including thiazide diuretics, corticosteroids, thyroid products, and estrogens, may impair glycemic control and necessitate dose adjustments.

Adverse reactions

The most frequent adverse reactions associated with Glucophage involve the gastrointestinal system and occur predominantly during initiation of therapy. Common adverse effects include diarrhea, nausea, vomiting, abdominal bloating, flatulence, anorexia, and an unpleasant metallic taste. These symptoms are typically dose-dependent, transient, and resolve spontaneously or upon dosage reduction. Long-term treatment with metformin has been associated with a progressive decrease in serum vitamin B12 absorption, which may result in megaloblastic anemia or peripheral neuropathy. Routine monitoring of blood parameters every 1 to 2 years is recommended for patients on extended maintenance therapy.

Important precautions

Glucophage carries a Boxed Warning regarding the risk of lactic acidosis, a rare but severe and potentially fatal metabolic complication characterized by elevated blood lactate levels (>5 mmol/L), metabolic acidosis, and hypothermia. Risk factors include renal impairment, advanced age, acute heart failure, hypoxemia, surgical procedures, excessive alcohol intake, and liver impairment. Initiation is contraindicated in patients with an eGFR below 30 mL/min/1.73 m², and initiation is not recommended in patients with an eGFR between 30 and 45 mL/min/1.73 m². Special caution must be exercised in geriatric populations due to age-related declines in renal filtration capacity.

Food and alcohol interactions

Administering Glucophage with meals substantially improves gastrointestinal tolerability without compromising overall therapeutic efficacy. Alcohol is known to potentiate the effect of metformin on lactate metabolism, significantly increasing the risk of lactic acidosis. Patients should be explicitly cautioned against acute binge drinking or chronic excessive alcohol consumption while taking Glucophage.

Red flags

Immediate medical evaluation in an emergency setting is required if signs of lactic acidosis appear. Patients or caregivers must seek urgent medical care if any of the following symptoms develop:

  • Severe fatigue, malaise, or unusual muscle pain;
  • Trouble breathing or rapid, shallow respiration;
  • Unexplained abdominal pain accompanied by nausea and vomiting;
  • Feeling unusually cold, particularly in the arms and legs;
  • Dizziness, lightheadedness, or a sudden slow or irregular heart rhythm.

Missed dose

If a dose of Glucophage is missed, it should be taken as soon as remembered with food, unless it is almost time for the next scheduled dose. Patients should not double the dose to make up for a missed tablet. Maintaining consistent administration with daily meals helps ensure steady blood levels and minimal gastrointestinal upset.

Day-to-day use

Routine daily management involves regular self-monitoring of blood glucose levels as recommended by the treating clinician. Tablets should be swallowed whole with a glass of water during or immediately after meals. Patients should maintain adequate daily fluid intake and adhere strictly to prescribed dietary guidelines, physical activity regimens, and scheduled clinical blood testing, including glycated hemoglobin (HbA1c) and renal function panels.

Common questions

Can Glucophage cause low blood sugar (hypoglycemia)?

When used as monotherapy, Glucophage typically does not cause hypoglycemia because it does not stimulate pancreatic insulin secretion. However, the risk of hypoglycemia increases if Glucophage is taken in combination with insulin or insulin secretagogues such as sulfonylureas, or during periods of inadequate caloric intake or strenuous exercise.

What should be done before undergoing an X-ray or CT scan with contrast dye?

Intravascular administration of iodinated contrast materials in radiological studies can lead to an acute decline in renal function, increasing the risk of lactic acidosis. Healthcare providers usually advise withholding Glucophage prior to or at the time of the procedure, resuming treatment only 48 hours later after renal function has been re-evaluated and confirmed stable.

How long does it take for Glucophage to show clinical effects?

Initial reductions in fasting blood glucose levels may be observed within 1 to 2 weeks of starting therapy, but full therapeutic stabilization and optimal glycemic control generally take several weeks of consistent dosing and dose titration.

Is routine blood testing necessary while taking Glucophage?

Yes, patients taking Glucophage require regular laboratory monitoring. Physicians periodically order tests to measure glycated hemoglobin (HbA1c), renal function (eGFR and serum creatinine), liver function, and serum vitamin B12 levels to ensure safety and therapeutic efficacy.

Can Glucophage be stopped abruptly?

Glucophage should not be discontinued without consulting a healthcare provider. Sudden cessation of antihyperglycemic therapy can lead to rapid elevations in blood glucose levels, worsening glycemic control and potentially requiring regimen adjustments.

In accordance with FDA regulatory guidelines for prescription medication information.

This text is for informational purposes only and does not constitute individual medical advice. Always consult your healthcare provider before starting or changing any treatment.

Additional information
Dosage

250 mg

,

500mg

,

850mg

,

1000mg

Package

60 pills

,

90 pills

,

120 pills

,

180 pills

,

270 pills

,

360 pills

Ενεργός Ουσία